British pharmaceutical group GSK on Wednesday raised its full-year outlook after strong sales growth in its third quarter, brushing off the potential impact of US tariffs.

Profit after tax stood at £2 billion ($2.7 billion) in the quarter, compared with a net loss of £58 million one year earlier linked to hefty US lawsuit settlements.

Revenue rose to £8.5 billion, driven by sales growth in its specialty medicines, including HIV and oncology.

The third-quarter earnings report is chief executive Emma Walmsley's last before chief commercial office Luke Miels takes over in January, as the company navigates the uncertainty of US tariffs on the sector.

GSK, which makes medicines in the European Union as well as Britain and the United States, said its updated guidance accounts for "tariffs en

See Full Page